Insect Cell Engineering

Sf9 Cell Pathway Optimization Service

Custom CRISPR-mediated engineering to reprogram metabolic and expression pathways in Sf9 cells for improved protein yields and process

Targeted pathway modification in clonal Sf9 isolates
Transcriptional or metabolic pathway redesign
Scalable from research shake-flasks to production bioreactors

Start your optimization project

Streamline your Sf9 cell line development with targeted pathway engineering.

Our service integrates bioinformatic pathway analysis, CRISPR design, single-cell cloning, and genotypic/phenotypic QC to deliver edited Sf9 cells ready for baculovirus-based expression.

Custom sgRNA library for up to 5 targets per pathway
Isogenic clone isolation with verified editing
Optional targeted amplicon sequencing for off-target assessment

Custom design

QC verified

Scalable

Our approach

From pathway analysis to stable edited clones

We combine computational target prediction, high-efficiency transfection, and rigorous clone screening to deliver Sf9 cell lines with optimized pathways.

Pathway analysis & target design

We review your target pathway using available metabolic and genomic data for Sf9 cells, then design CRISPR guides to knock out or modify key genes involved in nutrient utilization, protein folding, or viral replication.

Bioinformatic pathway mapping using Sf9 transcriptome data
Custom sgRNA design with on-target scoring
In silico off-target prediction (Cas-OFFinder)

Clone isolation & genotyping

Following transfection and antibiotic selection, we perform single-cell cloning using limiting dilution or automated colony picking. Each clone is genotyped by Sanger sequencing to confirm editing, with optional amplicon sequencing for off-target sites.

Single-cell cloning from bulk edited pools
Sanger sequencing of target loci (both alleles)
Optional targeted amplicon NGS for off-target assessment

Custom sgRNA library

We design and synthesize up to five sgRNAs per target to maximize editing efficiency in polyploid Sf9 cells.

Transfection optimization

Transfection conditions (cell density, lipid reagent, DNA ratio) are optimized for Sf9 suspension cultures to ensure high editing rates.

Clone screening & validation

Isogenic clones are screened by targeted sequencing and, when applicable, by functional assays (e.g., protein expression, growth kinetics).

Deliverables

What you receive

Each project delivers a clonal Sf9 cell line with documented editing along with comprehensive QC data.

Cell line deliverables

Cryopreserved edited Sf9 clone(s) – quantity scoped per project
Master cell bank (≥4 vials per clone)
Expanded clone validation data (growth curve, viability)

Documentation & QC

Sanger sequencing traces confirming on-target editing
In silico off-target analysis report
Optional targeted amplicon sequencing results (when scoped)
Project report with methods and acceptance criteria

Service scope

Case-by-case project configuration

Parameters are defined during consultation to match your specific pathway and timeline needs.

Parameter	Typical project scope
Target pathway	Selected by client; bioinformatic analysis of up to 5 genes per pathway
sgRNA design	2–4 sgRNAs per target (custom designed based on Sf9 genome)
Clone isolation method	Limiting dilution or automated colony picking, as scoped
Genotyping depth	Sanger sequencing of each clone at target locus; optional NGS panel for off-target
QC assays	Growth curve, viability, mycoplasma testing; functional assay as scoped

How it works

A streamlined pathway optimization workflow

From target selection to clone delivery, our process is designed for efficiency and reproducibility in Sf9 cells.

Project consultation & target selection

We discuss your pathway of interest (e.g., metabolic, secretion, apoptosis) and review available Sf9 transcriptomic or proteomic data to prioritize genes for modification.

CRISPR design & vector construction

sgRNAs are designed using Sf9 codon-optimized Cas9 and cloned into a suitable expression vector. Guides are synthesized and sequence-verified before transfection.

Transfection & bulk pool enrichment

Sf9 cells are co-transfected with Cas9 and sgRNA plasmids in suspension culture. After transient expression, bulk edited pools are enriched by antibiotic selection for 7–10 days.

Single-cell cloning & genotyping

Single cells are isolated by limiting dilution in conditioned medium. Genomic DNA is extracted and target loci are amplified by PCR and Sanger sequenced to identify homozygous or compound heterozygous edits.

Quality control & delivery

Confirmed edited clones are expanded, tested for mycoplasma and viability, and cryopreserved. A detailed project report with sequencing traces and QC data is provided.

Applications

Where Sf9 pathway optimization adds value

Modified Sf9 cells can improve recombinant protein production, enable novel product profiles, and support scale-up processes.

Enhance expression of difficult-to-produce proteins

By knocking out genes involved in apoptosis or nutrient depletion, we can extend the production phase of baculovirus-infected Sf9 cultures, leading to higher volumetric yields.

Increased product titers in shake-flask studies
Extended viable cell density during infection
Compatible with existing baculovirus vectors

Redirect carbon and energy flux toward product synthesis

Modifying central metabolic pathways (e.g., glycolysis, TCA cycle) in Sf9 cells can reduce byproduct accumulation and improve precursor availability for recombinant protein glycosylation or heterologous pathways.

Reduced lactate and ammonia accumulation
Improved specific productivity per cell
Customizable for secreted or membrane proteins

Develop Sf9 clones with consistent performance across passages

Editing genes involved in cell adhesion or cell cycle regulation can improve clonal stability, reducing variability in protein expression during scale-up and long-term culture.

Minimized loss of productivity over 20+ passages
Consistent growth kinetics in suspension
Suitable for GMP process development

Frequently asked questions

Common questions about Sf9 pathway optimization

Find answers to typical concerns about feasibility, QC, and turn-around.

Yes. We design multiplex sgRNA libraries to knock out or modify up to five genes in one transfection round. The editing efficiency per target is project-dependent and influenced by the polyploid nature of Sf9 cells; we report the proportion of multi-edited clones after single-cell isolation.
We perform Sanger sequencing across all alleles for each target. For polyploid Sf9 cells, we determine the number of modified alleles and select clones with desired editing patterns (e.g., knockout of all functional copies). The sequencing data is provided in the final report.
We conduct in silico off-target prediction using Cas-OFFinder against the Sf9 genome (when available) or a representative lepidopteran genome. For additional confidence, we offer targeted amplicon sequencing of the top 5–10 predicted off-target sites per sgRNA. Note that whole-genome off-target assays like GUIDE-seq have not been validated in Sf9 and are not offered as standard.
Each clone is tested for mycoplasma, viability post-thaw, and growth kinetics over at least three passages. We also confirm editing stability by re-sequencing the target locus after expansion. Functional assays (e.g., protein expression titer) are performed if scoped in the project agreement.

Scientific Literature

References

Laurent M, Geoffroy M, Pavani G, et al. CRISPR-Based Gene Therapies: From Preclinical to Clinical Treatments. Cells. 2024;13(10). View on PubMed
Song B, Bae S. Genome editing using CRISPR, CAST, and Fanzor systems. Molecules and cells. 2024;47(7):100086. View on PubMed
Pilon A, Goven D, Raymond V. Pharmacological and molecular characterization of the A-type muscarinic acetylcholine receptor from Anopheles gambiae. Insect molecular biology. 2022;31(4):497-507. View on PubMed
Tang Z, Luo W, Huang Z, et al. Spodoptera frugiperda mRNA export factor interacts with and mediates the nuclear import of Autographa californica multiple nucleopolyhedrovirus ORF34 (Ac34). Virus research. 2021;299:198438. View on PubMed
Datlinger P, Rendeiro AF, Schmidl C, et al. Pooled CRISPR screening with single-cell transcriptome readout. Nature methods. 2017;14(3):297-301. View on PubMed
Savić N, Schwank G. Advances in therapeutic CRISPR/Cas9 genome editing. Translational research: the journal of laboratory and clinical medicine. 2016;168:15-21. View on PubMed
Dixit A, Parnas O, Li B, et al. Perturb-Seq: Dissecting Molecular Circuits with Scalable Single-Cell RNA Profiling of Pooled Genetic Screens. Cell. 2016;167(7):1853-1866.e17. View on PubMed
Khan FA, Pandupuspitasari NS, Chun-Jie H, et al. CRISPR/Cas9 therapeutics: a cure for cancer and other genetic diseases. Oncotarget. 2016;7(32):52541-52552. View on PubMed

Ready to Start Your Project?

Get a customized quote for your Sf9 Cell Pathway Optimization Service project. Our experts will respond within 24 hours.

No obligation

24h response

Expert consultation